Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: A cohort study

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 4, 2016, Pages 695-703

  Biedermann, J S ^a,b   van Rein, N ^c   van den Besselaar, A M H P ^c   Buhre, P N ^b   de Maat, M P M ^a   van der Meer, F J M ^c   Leebeek, F W G ^a   Kruip, M J H A ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Blood coagulation tests; International normalized ratio; Point of care testing; Vitamin K antagonist

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; PHENPROCOUMON; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; COAGULOMETER; COHORT ANALYSIS; CONTROLLED STUDY; DUTCHMAN; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; POINT OF CARE TESTING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; FOLLOW UP; HEALTH CARE QUALITY; HEART VALVE PROSTHESIS; KAPLAN MEIER METHOD; MIDDLE AGED; PHYSIOLOGIC MONITORING; POINT OF CARE SYSTEM; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POINT-OF-CARE SYSTEMS; PROPORTIONAL HAZARDS MODELS; QUALITY OF HEALTH CARE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84962711787     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13272     Document Type: Article

References (26)

1. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-84S.
2. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-45.
3. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
4. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106: 968-77.
5. Federation of Dutch Thrombosis Services. Summary annual medical reports 2013. http://www.fnt.nl/. Accessed 18 February 2014.
6. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. J Thromb Thrombolysis 1996; 3: 377-83.
7. Health Quality Ontario. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ont Health Technol Assess Ser 2009; 9: 1-114.
8. Shiach CR, Campbell B, Poller L, Keown M, Chauhan N. Reliability of point-of-care prothrombin time testing in a community clinic: a randomized crossover comparison with hospital laboratory testing. Br J Haematol 2002; 119: 370-5.
9. Fitzmaurice DA. Oral anticoagulation control: the European perspective. J Thromb Thrombolysis 2006; 21: 95-100.
10. Federation of Dutch Thrombosis Services. De kunst van het doseren [in Dutch], 3rd edn, 2014. http://www.fnt.nl. Accessed 18 February 2014.
11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
12. Azar AJ, Cannegieter SC, Deckers JW, Briet E, van Bergen PF, Jonker JJ, Rosendaal FR. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27: 1349-55.
13. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-91.
14. Christensen TD, Larsen TB. Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost 2012; 10: 251-60.
15. Biedermann JS, Leebeek FW, Buhre PN, de Lathouder S, Barends JP, de Maat MP, van der Meer FJ, Kruip MJ. Agreement between Coaguchek XS and STA-R Evolution (Hepato Quick) INR results depends on the level of INR. Thromb Res 2015; 136: 652-7.
16. Solvik UO, Roraas T, Petersen PH, Stavelin A, Monsen G, Sandberg S. The influence of coagulation factors on the in-treatment biological variation of international normalized ratio for patients on warfarin. Scand J Clin Lab Invest 2014; 74: 470-6.
17. Kortke H, Minami K, Breymann T, Seifert D, Baraktaris A, Wagner O, Kleikamp G, El-Banayosy A, Mirow N, Korfer R. [INR Self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial)] INR-Selbstmanagement nach mechanischem Herzklappenersatz: ESCAT (Early Self-Controlled Anticoagulation Trial). Z Kardiol 2001; 90: 118-24.
18. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, Sandhar H, Hobbs FD. Self management of oral anticoagulation: randomised trial. BMJ 2005; 331: 1057.
19. Christensen TD, Maegaard M, Sorensen HT, Hjortdal VE, Hasenkam JM. Self-management versus conventional management of oral anticoagulant therapy: a randomized, controlled trial. Eur J Intern Med 2006; 17: 260-6.
20. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, Vertrees JE, Shih MC, Holodniy M, Lavori P, Committee TE, Site I. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010; 363: 1608-20.
21. Menendez-Jandula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, Bonfill X, Fontcuberta J. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 2005; 142: 1-10.
22. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U; SPOG 60 + Study Group. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb Haemost 2008; 100: 1089-98.
23. Kaatz S, Elston-Lafata J, Gooldy S. Anticoagulation therapy home and office monitoring evaluation study. J Thromb Thrombolysis 2001; 12: 111.
24. Heneghan C, Ward A, Perera R; Self-Monitoring Trialist Collaboration, Bankhead C, Fuller A, Stevens R, Bradford K, Tyndel S, Alonso-Coello P, Ansell J, Beyth R, Bernardo A, Christensen TD, Cromheecke ME, Edson RG, Fitzmaurice D, Gadisseur AP, Garcia-Alamino JM, Gardiner C, Hasenkam JM, Jacobson A, Kaatz S, Kamali F, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-34.
25. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost 2004; 2: 584-91.
26. Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-7.